Tiagabine: The Safety Landscape

  title={Tiagabine: The Safety Landscape},
  author={Ilo E. Leppik},
  • I. Leppik
  • Published 1 June 1995
  • Medicine, Psychology
  • Epilepsia
Summary: Tiagabine (TGB) hydrochloride is a potential new antiepileptic drug (AED) undergoing clinical development. Experience in humans amounts to 1,810 patient‐years of exposure. TGB was found to be tolerated in an integrated safety analysis of five double‐blind, add‐on therapy trials involving approximately 1,000 patients with epilepsy with difficult‐to‐control seizures with existing AEDs. Discontinuation resulting from adverse events were infrequent, occurring in 15% of patients receiving… 


Tiagabine (TGB) is a recently approved antiepileptic drug (AED) that inhibits γ‐aminobutyric acid (GABA) reuptake into neurons and glia, a mechanism of action that is specific and unique among the

Tiagabine in the Management of Epilepsy

Tiagabine (TGB) is a new antiepileptic drug (AED) that uniquely reduces the uptake of the inhibitory neurotransmitter ‐γ‐aminobutyric acid into presynaptic neuronal and glial cells that will find an enduring place in the management of epilepsy.

Tiagabine in Clinical Practice

In daily practice, tiagabine (TGB) appears to be a safe drug, but mild to moderate side effects are frequently seen, especially during titration: these include dizziness and fatigue, and are clearly abated when the drug is absorbed during meals.

Review of Controlled Trials of Gabitril (Tiagabine): A Clinician's Viewpoint

TGB efficacy in partial seizures was supported in several open trials, and no tolerance to efficacy was noted in long‐term continuation studies, and Tolerability was documented in all trials.

Tiagabine Monotherapy in the Treatment of Partial Epilepsy

These initial trials in difficult‐to‐treat epilepsy patients indicate that TGB monotherapy may provide a new approach to the treatment of patients with partial seizures refractory to other AEDs.

Safety of long-term treatment with tiagabine

The most important predictor of long-term therapy with tiagabine was the degree of seizure improvement; the adverse event profile was comparable among the three groups, and seizure frequency was significantly more improved in the > 24 months group.

Possible drug-induced thrombocytopenia secondary to tiagabine

A case of severe thrombocytopenia associated with tiagabine adjunctive therapy is described in a 42-year-old woman with intractable cryptogenic focal epilepsy and without other neurologic findings.

Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.

Tiagabine is a new antiepileptic agent with a novel mechanism of action, which has demonstrated efficacy in the adjunctive treatment of patients with refractory partial epilepsy and its relative merits in relation to other antiePileptic drugs.



International Experience with Tiagabine Add‐On Therapy

Summary: Tiagabine (TGB) hydrochloride is a novel antiepileptic drug (AED) that is a potent and specific inhibitor of γ‐aminobutyric acid (GABA) uptake into glial and neuronal elements. In accordance

Antiepileptic Drugs in Development: Prospects for the Near Future

Summary: Among some 14 new antiepileptic drugs (AEDs), those most extensively tested in humans include felbamate (FBM), gabapentin (GBP), lamotrigine (LTG), oxcarbazepine (OCBZ), vigabatrin (VGB),

Risk Factors for Idiopathic Generalized Seizures: A Population‐Based Case Control Study in Copparo, Italy

The data support the hypothesis of genetic propensity for generalized and febrile seizures, which may represent early expression of a low seizure threshold that subsequently de‐ velops into epilepsy.

Tiagabine Pharmacology in Profile

Summary: Tiagabine (TGB) hydrochloride, a nipecotic acid derivative linked to a lipophilic anchor, potently and specifically inhibits uptake of the inhibitory neurotransmitter γ‐aminobu‐tyric acid

Tiagabine. Epilepsia 1994;35 (suppl 5):S81-4

  • 1994

Andersen KE , Knutsen US , Sonnewald U , Braestrup C . Tiagabine

    Prospective study of death in epilepsy

    • Epilepsia
    • 1995